• UCB entered a strategic collaboration with Cradle today to expand its digital antibody discovery and engineering capabilities.
• Cradle's AI-driven protein engineering platform will support selected discovery projects from hit generation through lead optimization and preclinical readiness.
• The collaboration aims to accelerate identification and optimization of high-quality drug candidates for severe diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UCB SA published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.